Rocket Pharmaceuticals (RCKT) Non-Current Assets (2014 - 2026)

Rocket Pharmaceuticals has reported Non-Current Assets for 13 years, with the latest figure at $135.6 million in Q1 2026.

• Quarterly Non-Current Assets fell 7.5% year-over-year to $135.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $557.5 million (down 7.35% YoY) and the FY2025 annual result came in at $137.7 million, down 7.89% from the prior year.
• Non-Current Assets fell to $135.6 million in Q1 2026 per RCKT's latest filing, from $137.7 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $188.1 million in Q4 2023 and troughed at -$445.2 million in Q3 2023.
• A 5-year average of -$22.9 million and a median of $140.4 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets plunged 43.9% in 2023, then soared 149.45% in 2024.
• Over 5 years, Non-Current Assets stood at $187.7 million in 2022, then gained by 0.2% to $188.1 million in 2023, then fell by 20.52% to $149.5 million in 2024, then retreated by 7.89% to $137.7 million in 2025, then declined by 1.55% to $135.6 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $135.6 million, $137.7 million, and $140.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.